Pfizer, BioNTech say COVID-19 booster shot showed high 95.6% efficacy in large study

Pfizer, BioNTech say COVID-19 booster shot showed high efficacy in large study A booster dose of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE restored efficacy to 95.6% against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday. Reuters Reuters

BERLIN, Oct 21 (Reuters) - A booster dose of the COVID-19 vaccine developed by Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) restored efficacy to 95.6% against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday.

The companies said in a press release the trial, which has not been peer-reviewed, tested 10,000 participants aged 16 and older, and found that the booster shot had a favourable safety profile.

The trial results come a day after the U.S. Food and Drug Administration authorized booster doses of the COVID-19 vaccines from Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N), and said Americans could choose a different shot from their original inoculation as a booster.

The agency previously authorized boosters of the Pfizer/BioNTech shot at least six months after the first round of shots to increase protection for people aged 65 and older, those at risk of severe disease and those who are exposed to the virus through their work. ...

ALSO SEE: Pfizer vaccine very effective against Delta variant in adolescents in Israel - study